Neutrophil‐to‐lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non‐small‐cell lung cancer

BACKGROUND: Although phase III trials have shown improved overall and progression‐free survival (PFS) using nivolumab compared to docetaxel in patients with non‐small‐cell lung cancer, the progressive disease ratio of nivolumab is higher than docetaxel. Furthermore, nonconventional response patterns...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Takayuki, Takeuchi, Mayumi, Saitoh, Masahiko, Takeda, Sorou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166075/
https://www.ncbi.nlm.nih.gov/pubmed/30126063
http://dx.doi.org/10.1111/1759-7714.12838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166075/
https://www.ncbi.nlm.nih.gov/pubmed/30126063
http://dx.doi.org/10.1111/1759-7714.12838

Ejemplares similares